I am riding 85 miles @PanMass to raise funds for @DFarberYoungCRC Please support if you can! https://t.co/D29C1Qg46R

Safety of ICI Rechallenge Following irAEs Recurrence rate for the same irAE ✅Pneumonitis: 20-31% ✅Hepatitis: 22-35% ✅Colitis: 34-39% 👉ASCO, ESMO, and NCCN guidelines are summarized in the following review article in JJCO. https://t.co/FJPfKjwS0R @OncoAlert

Proud mentee moments Learning the art of grant writing with Dr Khorana @aakonc has been such a privilege. The thought process, discipline, and vision behind every line remind me why mentorship matters. #MedTwitter #Oncology #asco

Important paper. The dogma/SOC is locally recurrent or persistent anal SCC requires APR, but some pts decline surgery or tumors inoperable. In this series, 39Gy in 1.5Gy BID lead to CR in 46%, suggesting many tumors still radiosensitive & reRT can achieve durable LC. @OncoAlert

Today is World #PancreaticCancer Day and at @DanaFarber, we are lighting our Healing Garden purple tonight to raise awareness. Read more here about three ways research could improve pancreatic cancer treatment: https://t.co/zsDTPUzA7J @DanaFarber_Hale

It is so exciting to see the final version of our collaborative work with @LabSethi. We found that blocking HDAC1/2 pushes CRC cells out of a stem-like state and into differentiation. We will work tother more to find novel therapeutic options for CRC.

Very excited to see this in print. Our latest commentary highlighting the "missing piece of the puzzle" in neuroendocrine neoplasm classification, published in Med @CellPressNews . NENs are classified based on morphology, site of origin, and Ki-67 proliferation indices. These

Kicking off the first annual Young Adult Cancer Symposium! Excited to be here among like-minded patients, survivors, caregivers, advocates and healthcare professionals dedicated to take action to figure out why young adults are getting cancer at an alarming rate! #AYACSM

On @NPR @MorningEdition, @DanaFarber’s Dr. Ben Schlechter (@ben_schlechter) underscores the role of healthy eating in colorectal cancer prevention as new research associates ultra-processed foods to higher risk. https://t.co/qtdNG3SVHC CC: @DFarberYoungCRC

@allisonoconn @JamesClearyMD A pancreatic cancer precursor lesion (Pancreatic intraepithelial neoplasia or PanIN) with complete loss of MTAP expression secondary to a p16 homozygous deletion. The normal ductal epithelium retains expression.

Recurrence Patterns of Esophageal Adenocarcinoma in the ESOPEC Trial Comparing Perioperative CTx With Preoperative Chemoradiotherapy @JCO_ASCO https://t.co/FN6K1rdWeV 👉similar locoregional recurrence 👉less Distant recurrence with FLOT 🧐FLOT improved OS through better systemic

Unlike the G12Cmutation, which has a cysteine residue that can be targeted by covalent inhibitors, G12R lacks this specific residue, requiring different approaches. Very interesting idea for KRAS G12 R mutations @Dr_R_Kurzrock cc’ @Aiims1742 @DavidHongMD

Another @VanAllenLab @DanaFarber_GU collaboration with our friend @BraunMDPhD + many super stars like @Chrislabaki1 @eddy_saad @ZiadBakouny et al (all co-mentored @VanAllenLab)--we will unlock biomarkers of IO resistance in RCC, 1 step at a time. cc: @DanaFarber_GU @ImmunityCP

👇🏽This is an excellent read 📕 📖 🔖 if you get a chance @JCO_ASCO #TumorBoardTuesday

🔥off the press🔥 LEAP-012 phase 3 study: TACE with lenvatinib + pembrolizumab vs plc for intermediate stage HCC 👉IA just released 👉PFS benefit maintained 👉No OS benefit, study stopped 🧐How to implement in clinical practice? I still consider as an effective option for

👀this🧐thoughtful piece by Dr. @gagan_brar24 on utility of #ctDNA🩸🧬 in non-metastatic rectal #cancer. As we talk about organ sparing approaches, a number of scenarios to keep in mind👇🏽. 💡ctDNA “origin”💦 would be of value in these circumstances. @OncoAlert @OncJournal📚🗞️

Happy to share that the data we presented at #ASCO2025 @ASCO (and many more details) are now published in @JCOPO_ASCO : Whole-body MRI (WBMRI) among individuals with Li-Fraumeni Syndrome (LFS) @DanaFarberNews @DFCIPopSci https://t.co/tQvrU7XaFr

Last week's Colorectal Club was led by @ben_schlechter, who gave a fascinating talk about new immunotherapy approaches in #colorectalcancer. Works well for certain subsets of patients but comes with its own caveats @DanaFarber @KimmieNgMD

This month's Colorectal Club was honored to have Dr. Ramesh Shivdasani share some of his work on intestinal stem cell dynamics in adenoma formation. Very intriguing findings! @DanaFarber

cT3/T4 per CT identifies patients with dMMR colon cancer with substantial risk of recurrence despite FOLFOX: cT3N0: 84% 3-year DFS cT4N0: 70% 3-year DFS Of course, NICHE2 : 100% 3-year DFS for cT3/4 For patients with dMMR colon cancer cT3/T4 by CT: we should discuss risks and

Team Beyond CRC at this year's Jimmy Fund Walk! We are so grateful to have such an amazing team walking and fundraising for the Jimmy Fund and the Young-Onset Colorectal Cancer Center. @TheJimmyFund @DanaFarber @KimmieNgMD